Anti-myeloma specific T cell responses with increased secretion of IFN-γ, perforin and granzyme B were observed in a clinical trial of myeloma patients that received lenalidomide as consolidation therapy after ASCT (34). This evidence concerns the gene IFNG and plasma cell myeloma.